B. Riley Financial Issues Positive Forecast for Perspective Therapeutics (NYSEAMERICAN:CATX) Stock Price

Perspective Therapeutics (NYSEAMERICAN:CATX) had its price target lifted by analysts at B. Riley Financial from $11.00 to $13.00 in a research report issued on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. B. Riley Financial’s target price would indicate a potential upside of 165.20% from the stock’s previous close.

A number of other brokerages also recently issued reports on CATX. HC Wainwright lifted their price objective on shares of Perspective Therapeutics from $10.00 to $12.00 and gave the company a “buy” rating in a report on Friday, January 30th. Truist Financial set a $12.00 target price on Perspective Therapeutics in a research report on Tuesday. BTIG Research restated a “buy” rating and issued a $14.00 price target on shares of Perspective Therapeutics in a research note on Tuesday. UBS Group increased their price target on Perspective Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Piper Sandler initiated coverage on Perspective Therapeutics in a report on Thursday, February 19th. They issued an “overweight” rating and a $16.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $12.50.

Perspective Therapeutics Trading Down 1.0%

Shares of NYSEAMERICAN:CATX traded down $0.05 during trading hours on Wednesday, hitting $4.90. The company’s stock had a trading volume of 469,485 shares, compared to its average volume of 3,744,995. The firm’s fifty day moving average price is $4.26 and its 200 day moving average price is $3.42. The company has a current ratio of 8.66, a quick ratio of 8.66 and a debt-to-equity ratio of 0.01. Perspective Therapeutics has a 52 week low of $1.60 and a 52 week high of $6.16.

Perspective Therapeutics (NYSEAMERICAN:CATX) last released its quarterly earnings results on Monday, March 16th. The company reported ($0.51) earnings per share for the quarter. Perspective Therapeutics had a negative net margin of 9,841.86% and a negative return on equity of 40.03%. The firm had revenue of $0.04 million during the quarter. On average, sell-side analysts anticipate that Perspective Therapeutics will post -0.88 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Aigen Investment Management LP purchased a new position in shares of Perspective Therapeutics during the fourth quarter worth $28,000. Russell Investments Group Ltd. lifted its stake in Perspective Therapeutics by 184.1% during the 3rd quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company’s stock worth $29,000 after acquiring an additional 5,475 shares in the last quarter. nVerses Capital LLC acquired a new position in Perspective Therapeutics during the 4th quarter worth about $31,000. AXQ Capital LP boosted its holdings in Perspective Therapeutics by 24.2% during the 4th quarter. AXQ Capital LP now owns 12,749 shares of the company’s stock valued at $35,000 after acquiring an additional 2,481 shares during the period. Finally, Engineers Gate Manager LP purchased a new position in Perspective Therapeutics during the 4th quarter valued at about $35,000. Institutional investors and hedge funds own 54.66% of the company’s stock.

Perspective Therapeutics News Roundup

Here are the key news stories impacting Perspective Therapeutics this week:

• Positive Sentiment: Multiple analysts reaffirmed or raised ratings and targets, signaling buy-side interest—UBS raised its price target from $7 to $8 and kept a “buy” rating. UBS raises PT to $8
• Positive Sentiment: Wedbush reaffirmed an “Outperform” rating and set an $11 price target, reinforcing bullish analyst sentiment. Wedbush reafirms Outperform, $11 PT
• Positive Sentiment: BTIG reiterated a “Buy” rating with a $14 target, adding to a cluster of high price targets (some firms have targets in the low-mid double digits). BTIG reaffirms Buy, $14 PT
• Positive Sentiment: Perspective had updated [212Pb]VMT-α-NET data accepted for a poster at the AACR Annual Meeting (April 20 presentation). Earlier interim data showed no dose-limiting toxicities and encouraging signals of anti-tumor activity in several cohorts—this is a visible clinical catalyst that could drive sentiment if the full poster confirms efficacy/safety trends. AACR acceptance press release
• Neutral Sentiment: Company filed a business update and full-year 2025 report describing program progress and expansion of production/finishing capabilities—useful context for longer-term commercialization but not an immediate earnings catalyst. Business update & full-year 2025 results
• Negative Sentiment: Royal Bank of Canada trimmed its price target from $18 to $14 (still “Outperform”), reflecting some downward PT revisions despite maintaining constructive views—this may temper upside expectations. RBC lowers PT to $14
• Negative Sentiment: Recent quarterly results showed a loss (EPS -$0.51) and minimal revenue, highlighting ongoing cash burn and weak near-term financials; these fundamentals can pressure the stock absent clear path to commercialization or financing. Quarterly results / press release

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.